McKesson Corporation provides healthcare supply chain management, retail pharmacy, community oncology and specialty care, and healthcare information solutions in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment offers CoverMyMeds solution to help patients get the medications; RelayHealth, a workflow solution; RxCrossroads solution for therapies and interventions to biopharma manufacturers; and McKesson Prescription Automation, a customized pharmacy automation technology; and Multi-Client Central Fill as a Service, a pharmacy. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
IPO Year:
Exchange: NYSE
Website: mckesson.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/28/2026 | Outperform | William Blair | |
| 12/9/2025 | $960.00 | Overweight | Barclays |
| 12/4/2024 | $630.00 | Neutral | Mizuho |
| 11/7/2024 | $531.00 → $688.00 | Neutral → Outperform | Robert W. Baird |
| 9/24/2024 | $603.00 → $531.00 | Outperform → Neutral | Robert W. Baird |
| 9/5/2024 | $670.00 → $665.00 | Outperform | Leerink Partners |
| 8/8/2024 | $540.00 → $570.00 | Neutral | Mizuho |
| 2/26/2024 | $600.00 | Outperform | Leerink Partners |
| 1/3/2024 | $537.00 | Overweight | Barclays |
| 12/14/2023 | $502.00 | Equal Weight | Wells Fargo |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
William Blair initiated coverage of McKesson with a rating of Outperform
Barclays initiated coverage of McKesson with a rating of Overweight and set a new price target of $960.00
Mizuho resumed coverage of McKesson with a rating of Neutral and set a new price target of $630.00
Robert W. Baird upgraded McKesson from Neutral to Outperform and set a new price target of $688.00 from $531.00 previously
Robert W. Baird downgraded McKesson from Outperform to Neutral and set a new price target of $531.00 from $603.00 previously
Leerink Partners reiterated coverage of McKesson with a rating of Outperform and set a new price target of $665.00 from $670.00 previously
Mizuho reiterated coverage of McKesson with a rating of Neutral and set a new price target of $570.00 from $540.00 previously
Leerink Partners initiated coverage of McKesson with a rating of Outperform and set a new price target of $600.00
Barclays initiated coverage of McKesson with a rating of Overweight and set a new price target of $537.00
Wells Fargo initiated coverage of McKesson with a rating of Equal Weight and set a new price target of $502.00
SD - MCKESSON CORP (0000927653) (Filer)
8-K - MCKESSON CORP (0000927653) (Filer)
8-K - MCKESSON CORP (0000927653) (Filer)
8-K - MCKESSON CORP (0000927653) (Filer)
SCHEDULE 13G/A - MCKESSON CORP (0000927653) (Subject)
8-K - MCKESSON CORP (0000927653) (Filer)
8-K - MCKESSON CORP (0000927653) (Filer)
10-Q - MCKESSON CORP (0000927653) (Filer)
8-K - MCKESSON CORP (0000927653) (Filer)
25-NSE - MCKESSON CORP (0000927653) (Subject)
Fastest customizable press release news feed in the world
McKesson Corporation (NYSE:MCK) announced today the successful completion of the previously announced minority ownership interest investment from funds managed by affiliates of Apollo ("Apollo Funds") in McKesson's Medical-Surgical Solutions ("MMS") business on June 1, 2026. This transaction represents a key milestone in McKesson's intention to separate MMS into an independent, publicly traded company, and positions the business for long-term growth. Apollo Funds invested $1.25 billion in convertible preferred equity of MMS to acquire an approximately 13% interest in MMS. The transaction values MMS at approximately $13 billion total enterprise valuation. McKesson retains operating con
McKesson Corporation (NYSE:MCK) has released its fiscal 2026 fourth quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Thursday, May 7, at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at inves
The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 82 cents per share of common stock. The dividend will be payable on July 1, 2026, to shareholders of record on June 1, 2026. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and rea
McKesson Corporation (NYSE:MCK), a leading Healthcare Services company, today announced it has entered into a definitive agreement with funds managed by affiliates of Apollo ("Apollo Funds"), under which Apollo Funds will acquire a minority ownership interest in McKesson's Medical-Surgical Solutions ("MMS") business. This transaction represents a meaningful milestone as McKesson executes its separation strategy of MMS in preparation of a planned initial public offering. Apollo Funds will invest $1.25 billion in convertible preferred equity of MMS to acquire an approximately 13% minority interest in MMS. The transaction values MMS at approximately $13 billion total enterprise valuation. Mc
McKesson Corporation (NYSE:MCK) will release its fourth quarter fiscal 2026 financial results after market close on Thursday, May 7, 2026. Chief Executive Officer Brian Tyler and Chief Financial Officer Britt Vitalone will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. Mr. Vitalone will be participating in Leerink Partners Global Healthcare Conference and Barclays Global Healthcare Conference on Wednesday, March 11, 2026. Mr. Vitalone will also participate in the BofA Securities 2026 Healthcare Conference in May 2026. McKesson Corporation has reaffirmed fiscal 2026 full year outlook as previously issued on Febru
Britt Vitalone announces retirement, Kenny Cheung named as successor McKesson Corporation (NYSE:MCK) today announced Britt Vitalone, Executive Vice President and Chief Financial Officer (CFO), has elected to retire after a successful and distinguished 20-year career with the company, including more than eight years as CFO. Looking ahead, Kenny Cheung will join McKesson as Executive Vice President and CFO, effective May 29, 2026. "Britt is an exceptional partner and leader. He has been instrumental in advancing the company's financial performance, engaging with shareholders, and instilling a culture of financial discipline," said Brian Tyler, Chief Executive Officer, McKesson Corporation
McKesson Corporation (NYSE:MCK) has released its fiscal 2026 third quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, February 4 at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at i
McKesson Corporation (NYSE:MCK) announced today that it has closed the transaction to sell its retail and distribution businesses in Norway to NorgesGruppen, a privately owned retail group. McKesson announced on August 4, 2025, that it planned to divest Norway, included within the Other segment. The transaction represents the final step in McKesson's commitment to fully exit its European operations. This transaction will enable McKesson to focus strategy and capital allocation on expanding and accelerating its growth platforms within Oncology and Multispecialty and Biopharma Services. Additional details related to the divestiture will be provided on the Company's Fiscal Third Quarter
The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 82 cents per share of common stock. The dividend will be payable on April 1, 2026, to shareholders of record on March 2, 2026. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and r
McKesson Corporation (NYSE:MCK) will release its third quarter fiscal 2026 financial results after market close on Wednesday, February 4, 2026. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. The live and archived audio webcast will be available on McKesson's Investor Relations website. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - MCKESSON CORP (0000927653) (Issuer)
4 - MCKESSON CORP (0000927653) (Issuer)
4 - MCKESSON CORP (0000927653) (Issuer)
3 - MCKESSON CORP (0000927653) (Issuer)
4 - MCKESSON CORP (0000927653) (Issuer)
4 - MCKESSON CORP (0000927653) (Issuer)
4 - MCKESSON CORP (0000927653) (Issuer)
4 - MCKESSON CORP (0000927653) (Issuer)
4 - MCKESSON CORP (0000927653) (Issuer)
4 - MCKESSON CORP (0000927653) (Issuer)
Live finance-specific insights
McKesson Corporation (NYSE:MCK) has released its fiscal 2026 fourth quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Thursday, May 7, at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at inves
The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 82 cents per share of common stock. The dividend will be payable on July 1, 2026, to shareholders of record on June 1, 2026. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and rea
McKesson Corporation (NYSE:MCK) will release its fourth quarter fiscal 2026 financial results after market close on Thursday, May 7, 2026. Chief Executive Officer Brian Tyler and Chief Financial Officer Britt Vitalone will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. Mr. Vitalone will be participating in Leerink Partners Global Healthcare Conference and Barclays Global Healthcare Conference on Wednesday, March 11, 2026. Mr. Vitalone will also participate in the BofA Securities 2026 Healthcare Conference in May 2026. McKesson Corporation has reaffirmed fiscal 2026 full year outlook as previously issued on Febru
McKesson Corporation (NYSE:MCK) has released its fiscal 2026 third quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, February 4 at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at i
The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 82 cents per share of common stock. The dividend will be payable on April 1, 2026, to shareholders of record on March 2, 2026. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and r
McKesson Corporation (NYSE:MCK) will release its third quarter fiscal 2026 financial results after market close on Wednesday, February 4, 2026. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. The live and archived audio webcast will be available on McKesson's Investor Relations website. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to
The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 82 cents per share of common stock. The dividend will be payable on January 2, 2026 to shareholders of record on December 1, 2025. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com a
McKesson Corporation (NYSE:MCK) will host its 2025 Investor Day today, beginning at 9:30 AM ET. During the event, executive leadership will discuss the company's multi-year strategic priorities, growth strategies, and long-term business outlook. The Investor Day event will showcase how McKesson continues to accelerate long-term growth and deliver sustained value creation: Executing strategic priorities: Demonstrating significant progress, focusing on people and culture, strengthening North American Pharmaceutical distribution, modernizing and accelerating the portfolio, and expanding oncology, multispecialty, and biopharma services platforms. Advancing portfolio optimization: Provid
McKesson Corporation (NYSE:MCK) has released its fiscal 2026 first quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, August 6 at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at inv
The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of $0.82 per share of common stock, a 15% increase from $0.71 per share in the prior quarter. The dividend will be payable on October 1, 2025, to stockholders of record on September 2, 2025. "McKesson continues our long-standing track record of returning capital to shareholders, marking our ninth consecutive annual dividend increase," said Brian Tyler, chief executive officer. "These actions reflect our confidence in the strength of our business and reinforces our commitment to delivering long-term value to shareholders." About McKesson Corporation McKesson Corporation is a diversified heal
Live Leadership Updates
Britt Vitalone announces retirement, Kenny Cheung named as successor McKesson Corporation (NYSE:MCK) today announced Britt Vitalone, Executive Vice President and Chief Financial Officer (CFO), has elected to retire after a successful and distinguished 20-year career with the company, including more than eight years as CFO. Looking ahead, Kenny Cheung will join McKesson as Executive Vice President and CFO, effective May 29, 2026. "Britt is an exceptional partner and leader. He has been instrumental in advancing the company's financial performance, engaging with shareholders, and instilling a culture of financial discipline," said Brian Tyler, Chief Executive Officer, McKesson Corporation
Acquisition enhances McKesson's integrated oncology platform; Florida Cancer Specialists & Research Institute to join The US Oncology Network McKesson Corporation (NYSE:MCK) announced today that it signed a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures). Core Ventures, a business and administrative services organization, was established by Florida Cancer Specialists & Research Institute, LLC (FCS), a leading physician-owned community oncology practice. FCS physicians will continue to retain a minority interest in Core Ventures. McKesson will purchase its controlling interest for approximately $2.49 bil
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced that Edward Wholihan was appointed to the Company's Board of Directors on September 28, 2023 to fill the vacancy that followed the Company's 2023 Annual Meeting of Shareholders. "I am extremely proud to welcome a highly accomplished executive such as Ed to our Board of Directors. He will be a valuable addition and we will benefit from his breadth of experience and success creating shar
NORTHVILLE, Mich., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ:THRM), the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry and a leader in medical patient temperature management systems, today announced that Dr. Ken Washington has been appointed to the Company's Board of Directors, effective October 2, 2023. Dr. Washington is the Senior Vice President, Chief Technology and Innovation Officer of Medtronic plc (NYSE:MDT), a global healthcare technology company that provides device-based medical therapies and services. He was appointed to this position in June 2023, and he leads innovation and the expansion of technol
Highlights Entrenchment Tactics Taken by the Board Before and Following March Special Meeting Where Shareholders Overwhelmingly Supported Murchinson's Case for Change – Including the Removal of CEO and Chairman Yoav Stern From the Board Puts Forward Proposals to Improve Company's Failed Corporate Governance by Seeking to Remove All Current Directors and Appoint Five New, Experienced and Independent Nominees Murchinson Ltd. (collectively with its affiliates and funds it advises and/or sub-advises, "Murchinson" or "we"), a significant shareholder with approximately 5.9% of the outstanding shares of Nano Dimension Ltd., a company incorporated in Israel (NASDAQ:NNDM) ("Nano Dimension" or th
CALGARY, AB, Jan. 25, 2022 /CNW/ - Comprehensive Healthcare Systems Inc. (TSXV:CHS) (the "Company" or "CHS"), an industry leader in Healthcare Benefits Administration software and services, is pleased to announce the appointment of Chris Cosgrove as the Company's new President and Chief Executive Officer ("CEO") and to its board of directors effective February 1, 2022. Mr. Cosgrove has 25 years of management and leadership experience in the healthcare technology industry and will replace CHS founder, Dr. Hassan Mohaideen, who will continue in his role as Chairman of the board of directors (the "Board") and be appointed Chief Medical Officer of the Company. "With a proven track record of lea
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Pam Randhawa was appointed to serve as a member of its board of directors, effective November 1, 2021. Ms. Randhawa is a thought leader within the life sciences sector and an experienced industry executive, with more than 20 years of experience leading public and private companies, ranging from biotech, healthcare and sustainable solutions, through their various stages of growth. Ms. Randhawa will ser
This live feed shows all institutional transactions in real time.
SC 13G/A - MCKESSON CORP (0000927653) (Subject)
SC 13G/A - MCKESSON CORP (0000927653) (Subject)
SC 13G/A - MCKESSON CORP (0000927653) (Subject)
SC 13G/A - MCKESSON CORP (0000927653) (Subject)
SC 13G/A - MCKESSON CORP (0000927653) (Subject)